Post-apoptotic tumors are more palatable to dendritic cells and enhance their antigen cross-presentation activity

Davide Brusa, Stefano Garetto, Giovanna Chiorino, Maria Scatolini, Elisa Migliore, Giovanni Camussi, Lina Matera

Research output: Contribution to journalArticle

43 Citations (Scopus)

Abstract

Critical issues for cytotoxic lymphocyte (CTL) cross-priming are (a) the maturation state of dendritic cells (DC), (b) the source of the tumor-associated antigens (TAA) and (c) the context in which they are delivered to DCs. Drug-induced apoptosis has recently been implicated in CTL cross-priming. However, since drug-treatment produces in vivo more tumor cells than the DC default apoptotic clearance program can cope with, they are expected to proceed to secondary necrosis and change their molecular pattern. Here we have addressed this issue on renal carcinoma cells (RCC) by using different apoptotic stimuli. UVC, but not γ-irradiation or anthracyclins, induced after 4 h treatment of the RCC cell line K1 a combination of apoptotic (phosphatydilserine and calreticulin plasma membrane mobilization) and necrotic (membrane incompetence) features. Heat shock protein (Hsp)-70 and chromatin-bound high mobility box 1 HMGB1 protein, typical of necrosis, were released during the further 20 h and thus made accessible to co-cultured monocyte-derived immature (i) DC. UVC-treated, secondary necrotic RCC cell lines were cross-presented with higher efficiency by cytokine-matured (m) DC than their early apoptotic (i.e. γ-irradiated) counterpart. Upstream events such as increased tumor uptake, activation of genes involved in the antigen-processing machinery, and increased expression of costimulatory and maturation molecules were also observed after loading iDC with secondary necrotic, but not apoptotic, tumor cells. These data offer a description of the molecular and immunogenic characteristics of post-apoptotic tumors which can be exploited to increase the efficiency of in vivo and ex vivo TAA delivery to the DC cross-presentation pathway.

Original languageEnglish
Pages (from-to)6422-6432
Number of pages11
JournalVaccine
Volume26
Issue number50
DOIs
Publication statusPublished - Nov 25 2008

Fingerprint

Cross-Priming
Antigen Presentation
dendritic cells
Dendritic Cells
antigens
neoplasms
Renal Cell Carcinoma
carcinoma
kidneys
Neoplasm Antigens
Neoplasms
necrosis
Necrosis
lymphocytes
cell lines
Lymphocytes
calreticulin
Calreticulin
HMGB1 Protein
Cell Line

Keywords

  • Antigen presentation
  • Apoptosis
  • Dendritic cells
  • Tumor immunity
  • Vaccination

ASJC Scopus subject areas

  • Immunology and Microbiology(all)
  • Infectious Diseases
  • Public Health, Environmental and Occupational Health
  • veterinary(all)
  • Molecular Medicine

Cite this

Brusa, D., Garetto, S., Chiorino, G., Scatolini, M., Migliore, E., Camussi, G., & Matera, L. (2008). Post-apoptotic tumors are more palatable to dendritic cells and enhance their antigen cross-presentation activity. Vaccine, 26(50), 6422-6432. https://doi.org/10.1016/j.vaccine.2008.08.063

Post-apoptotic tumors are more palatable to dendritic cells and enhance their antigen cross-presentation activity. / Brusa, Davide; Garetto, Stefano; Chiorino, Giovanna; Scatolini, Maria; Migliore, Elisa; Camussi, Giovanni; Matera, Lina.

In: Vaccine, Vol. 26, No. 50, 25.11.2008, p. 6422-6432.

Research output: Contribution to journalArticle

Brusa, D, Garetto, S, Chiorino, G, Scatolini, M, Migliore, E, Camussi, G & Matera, L 2008, 'Post-apoptotic tumors are more palatable to dendritic cells and enhance their antigen cross-presentation activity', Vaccine, vol. 26, no. 50, pp. 6422-6432. https://doi.org/10.1016/j.vaccine.2008.08.063
Brusa, Davide ; Garetto, Stefano ; Chiorino, Giovanna ; Scatolini, Maria ; Migliore, Elisa ; Camussi, Giovanni ; Matera, Lina. / Post-apoptotic tumors are more palatable to dendritic cells and enhance their antigen cross-presentation activity. In: Vaccine. 2008 ; Vol. 26, No. 50. pp. 6422-6432.
@article{a70df58d28e9442186c36436d2309e2b,
title = "Post-apoptotic tumors are more palatable to dendritic cells and enhance their antigen cross-presentation activity",
abstract = "Critical issues for cytotoxic lymphocyte (CTL) cross-priming are (a) the maturation state of dendritic cells (DC), (b) the source of the tumor-associated antigens (TAA) and (c) the context in which they are delivered to DCs. Drug-induced apoptosis has recently been implicated in CTL cross-priming. However, since drug-treatment produces in vivo more tumor cells than the DC default apoptotic clearance program can cope with, they are expected to proceed to secondary necrosis and change their molecular pattern. Here we have addressed this issue on renal carcinoma cells (RCC) by using different apoptotic stimuli. UVC, but not γ-irradiation or anthracyclins, induced after 4 h treatment of the RCC cell line K1 a combination of apoptotic (phosphatydilserine and calreticulin plasma membrane mobilization) and necrotic (membrane incompetence) features. Heat shock protein (Hsp)-70 and chromatin-bound high mobility box 1 HMGB1 protein, typical of necrosis, were released during the further 20 h and thus made accessible to co-cultured monocyte-derived immature (i) DC. UVC-treated, secondary necrotic RCC cell lines were cross-presented with higher efficiency by cytokine-matured (m) DC than their early apoptotic (i.e. γ-irradiated) counterpart. Upstream events such as increased tumor uptake, activation of genes involved in the antigen-processing machinery, and increased expression of costimulatory and maturation molecules were also observed after loading iDC with secondary necrotic, but not apoptotic, tumor cells. These data offer a description of the molecular and immunogenic characteristics of post-apoptotic tumors which can be exploited to increase the efficiency of in vivo and ex vivo TAA delivery to the DC cross-presentation pathway.",
keywords = "Antigen presentation, Apoptosis, Dendritic cells, Tumor immunity, Vaccination",
author = "Davide Brusa and Stefano Garetto and Giovanna Chiorino and Maria Scatolini and Elisa Migliore and Giovanni Camussi and Lina Matera",
year = "2008",
month = "11",
day = "25",
doi = "10.1016/j.vaccine.2008.08.063",
language = "English",
volume = "26",
pages = "6422--6432",
journal = "Vaccine",
issn = "0264-410X",
publisher = "Elsevier BV",
number = "50",

}

TY - JOUR

T1 - Post-apoptotic tumors are more palatable to dendritic cells and enhance their antigen cross-presentation activity

AU - Brusa, Davide

AU - Garetto, Stefano

AU - Chiorino, Giovanna

AU - Scatolini, Maria

AU - Migliore, Elisa

AU - Camussi, Giovanni

AU - Matera, Lina

PY - 2008/11/25

Y1 - 2008/11/25

N2 - Critical issues for cytotoxic lymphocyte (CTL) cross-priming are (a) the maturation state of dendritic cells (DC), (b) the source of the tumor-associated antigens (TAA) and (c) the context in which they are delivered to DCs. Drug-induced apoptosis has recently been implicated in CTL cross-priming. However, since drug-treatment produces in vivo more tumor cells than the DC default apoptotic clearance program can cope with, they are expected to proceed to secondary necrosis and change their molecular pattern. Here we have addressed this issue on renal carcinoma cells (RCC) by using different apoptotic stimuli. UVC, but not γ-irradiation or anthracyclins, induced after 4 h treatment of the RCC cell line K1 a combination of apoptotic (phosphatydilserine and calreticulin plasma membrane mobilization) and necrotic (membrane incompetence) features. Heat shock protein (Hsp)-70 and chromatin-bound high mobility box 1 HMGB1 protein, typical of necrosis, were released during the further 20 h and thus made accessible to co-cultured monocyte-derived immature (i) DC. UVC-treated, secondary necrotic RCC cell lines were cross-presented with higher efficiency by cytokine-matured (m) DC than their early apoptotic (i.e. γ-irradiated) counterpart. Upstream events such as increased tumor uptake, activation of genes involved in the antigen-processing machinery, and increased expression of costimulatory and maturation molecules were also observed after loading iDC with secondary necrotic, but not apoptotic, tumor cells. These data offer a description of the molecular and immunogenic characteristics of post-apoptotic tumors which can be exploited to increase the efficiency of in vivo and ex vivo TAA delivery to the DC cross-presentation pathway.

AB - Critical issues for cytotoxic lymphocyte (CTL) cross-priming are (a) the maturation state of dendritic cells (DC), (b) the source of the tumor-associated antigens (TAA) and (c) the context in which they are delivered to DCs. Drug-induced apoptosis has recently been implicated in CTL cross-priming. However, since drug-treatment produces in vivo more tumor cells than the DC default apoptotic clearance program can cope with, they are expected to proceed to secondary necrosis and change their molecular pattern. Here we have addressed this issue on renal carcinoma cells (RCC) by using different apoptotic stimuli. UVC, but not γ-irradiation or anthracyclins, induced after 4 h treatment of the RCC cell line K1 a combination of apoptotic (phosphatydilserine and calreticulin plasma membrane mobilization) and necrotic (membrane incompetence) features. Heat shock protein (Hsp)-70 and chromatin-bound high mobility box 1 HMGB1 protein, typical of necrosis, were released during the further 20 h and thus made accessible to co-cultured monocyte-derived immature (i) DC. UVC-treated, secondary necrotic RCC cell lines were cross-presented with higher efficiency by cytokine-matured (m) DC than their early apoptotic (i.e. γ-irradiated) counterpart. Upstream events such as increased tumor uptake, activation of genes involved in the antigen-processing machinery, and increased expression of costimulatory and maturation molecules were also observed after loading iDC with secondary necrotic, but not apoptotic, tumor cells. These data offer a description of the molecular and immunogenic characteristics of post-apoptotic tumors which can be exploited to increase the efficiency of in vivo and ex vivo TAA delivery to the DC cross-presentation pathway.

KW - Antigen presentation

KW - Apoptosis

KW - Dendritic cells

KW - Tumor immunity

KW - Vaccination

UR - http://www.scopus.com/inward/record.url?scp=55749106392&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=55749106392&partnerID=8YFLogxK

U2 - 10.1016/j.vaccine.2008.08.063

DO - 10.1016/j.vaccine.2008.08.063

M3 - Article

C2 - 18848858

AN - SCOPUS:55749106392

VL - 26

SP - 6422

EP - 6432

JO - Vaccine

JF - Vaccine

SN - 0264-410X

IS - 50

ER -